Xu SG - Search Results

1

UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic breast cancer.

Jin W, Chen L, Chen Y, Xu SG, Di GH, Yin WJ, Wu J, Shao ZM. Jin W, et al. Among authors: xu sg. Breast Cancer Res Treat. 2010 Sep;123(2):359-73. doi: 10.1007/s10549-009-0652-2. Epub 2009 Nov 27. Breast Cancer Res Treat. 2010. PMID: 19943104

2

UHRF1 inhibits MDR1 gene transcription and sensitizes breast cancer cells to anticancer drugs.

Jin W, Liu Y, Xu SG, Yin WJ, Li JJ, Yang JM, Shao ZM. Jin W, et al. Among authors: xu sg. Breast Cancer Res Treat. 2010 Nov;124(1):39-48. doi: 10.1007/s10549-009-0683-8. Breast Cancer Res Treat. 2010. PMID: 20037778

3

c-myb activates CXCL12 transcription in T47D and MCF7 breast cancer cells.

Chen L, Xu S, Zeng X, Li J, Yin W, Chen Y, Shao Z, Jin W. Chen L, et al. Acta Biochim Biophys Sin (Shanghai). 2010 Jan;42(1):1-7. doi: 10.1093/abbs/gmp108. Acta Biochim Biophys Sin (Shanghai). 2010. PMID: 20043041 Free article.

4

Differential proteomic analysis of a highly metastatic variant of human breast cancer cells using two-dimensional differential gel electrophoresis.

Xu SG, Yan PJ, Shao ZM. Xu SG, et al. J Cancer Res Clin Oncol. 2010 Oct;136(10):1545-56. doi: 10.1007/s00432-010-0812-0. Epub 2010 Feb 14. J Cancer Res Clin Oncol. 2010. PMID: 20155427

5

Downregulation of transgelin 2 promotes breast cancer metastasis by activating the reactive oxygen species/nuclear factor‑κB signaling pathway.

Yang L, Hong Q, Xu SG, Kuang XY, Di GH, Liu GY, Wu J, Shao ZM, Yu SJ. Yang L, et al. Among authors: xu sg. Mol Med Rep. 2019 Nov;20(5):4045-4258. doi: 10.3892/mmr.2019.10643. Epub 2019 Sep 3. Mol Med Rep. 2019. PMID: 31485630 Free PMC article.

6

Development of the expression and prognostic significance of m⁵ C-related LncRNAs in breast cancer.

Xu G, Li C, Di Z, Yang Y, Liang L, Yuan Q, Yang Q, Dong X, Xu S, Wu G. Xu G, et al. Cancer Med. 2023 Mar;12(6):7667-7681. doi: 10.1002/cam4.5500. Epub 2022 Dec 4. Cancer Med. 2023. PMID: 36464884 Free PMC article.

7

Differential roles of IRS-1 and SHC signaling pathways in breast cancer cells.

Nolan MK, Jankowska L, Prisco M, Xu S, Guvakova MA, Surmacz E. Nolan MK, et al. Int J Cancer. 1997 Sep 4;72(5):828-34. doi: 10.1002/(sici)1097-0215(19970904)72:5<828::aid-ijc20>3.0.co;2-3. Int J Cancer. 1997. PMID: 9311601

8

Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.

Xu S, Li S, Guo Z, Luo J, Ellis MJ, Ma CX. Xu S, et al. Mol Cancer Ther. 2013 Aug;12(8):1665-75. doi: 10.1158/1535-7163.MCT-13-0159. Epub 2013 May 20. Mol Cancer Ther. 2013. PMID: 23689832 Free PMC article.

9

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.

Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, Uesugi M, Agoulnik S, Taylor N, Funahashi Y, Matsui J. Yoshida T, et al. Br J Cancer. 2014 Mar 18;110(6):1497-505. doi: 10.1038/bjc.2014.80. Epub 2014 Feb 25. Br J Cancer. 2014. PMID: 24569463 Free PMC article.

10

Ecto-5'-nucleotidase (CD73) promotes tumor angiogenesis.

Wang L, Tang S, Wang Y, Xu S, Yu J, Zhi X, Ou Z, Yang J, Zhou P, Shao Z. Wang L, et al. Clin Exp Metastasis. 2013 Jun;30(5):671-80. doi: 10.1007/s10585-013-9571-z. Epub 2013 Mar 19. Clin Exp Metastasis. 2013. PMID: 23508889

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

150 results

Search Page

Filters